668 results on '"Eisenhauer E"'
Search Results
2. Real-world evidence in the treatment of ovarian cancer
3. EP13.01-012 Exploring Factors Affecting Variability in Lung Cancer Outcomes Across Southeastern Ontario, Canada
4. EP04.01-024 Influence of Lung Diagnostic Assessment Program on Health Resource Utilization in Lung Cancer in Southeastern Ontario, Canada
5. OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer
6. First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)—a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG
7. A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195
8. The European—Canadian study of paclitaxel in ovarian cancer. High vs low dose; long vs short infusion
9. A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas—NCIC-CTG IND 200†
10. Optimal assessment of response in ovarian cancer
11. A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial
12. SarCNU in recurrent or metastatic colorectal cancer: A phase II study of the National Cancer Institute of Canada Clinical Trials Group
13. A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers
14. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)
15. 3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration
16. Clinical trials in ovarian carcinoma: study methodology
17. Performance of multinomial designs in comparison with response-based designs in non-randomized phase II trials of targeted cancer agents
18. Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada – Clinical Trials Group (NCIC-CTG)
19. Health-related quality of life in recurrent platinum-sensitive ovarian cancer—results from the CALYPSO trial
20. Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179)
21. Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study
22. Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study
23. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study
24. Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin–Topotecan and Carboplatin–Paclitaxel vs Carboplatin–Paclitaxel
25. Phase I clinical study of didemnin B
26. Stopping a trial early in oncology: for patients or for industry?
27. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
28. Response evaluation: beyond RECIST
29. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150
30. New targets and non-cytotoxics in ovarian cancer
31. Abstracts for the Tenth International Conference on Brain Tumour Research and Therapy: Stalheim Hotel, Voss, Norway, September 6–9, 1993
32. A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers
33. A phase II study of menogaril in low-grade non-Hodgkin's lymphoma: An NCI Canada Clinical Trials Group study
34. A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly
35. DNA methyltransferase inhibitors—state of the art
36. Novel endpoints and design of early clinical trials
37. Surgery in Advanced Epithelial Ovarian Cancer
38. Application of a New Multinomial Phase II Stopping Rule Using Response and Early Progression
39. Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116)☆
40. Phase II Feasibility Study of Sequential Couplets of Cisplatin/Topotecan Followed by Paclitaxel/Cisplatin as Primary Treatment for Advanced Epithelial Ovarian Cancer: A National Cancer Institute of Canada Clinical Trials Group Study
41. A phase I-II study of 9-cis retinoic acid and interferon-α2b in patients with advanced renal-cell carcinoma: An NCIC Clinical Trials Group study
42. Phase I and II Evaluation of Novel Anticancer Agents: Are Response and Toxicity the Right Endpoints?
43. Phase I Clinical Trial Design in Cancer Drug Development
44. A Population-Based Study of Melanoma Brain Metastasis Treatment: Has Progress in Systemic Therapy and Radiation Therapy Improved Patient Outcomes?
45. Phase II study on DuP 937 (Teloxantrone) in colorectal carcinoma: A Canadian National Cancer Institute Clinical Trial Group study
46. 32 A population-based study of melanoma brain metastasis treatment: Has new progress in systemic therapy and new technology in radiotherapy improved patient outcomes?
47. Barriers to Participation in Clinical Trials: a Physician Survey
48. OV21/PETROC: A Randomized Gynecologic Cancer Intergroup Phase II Study of Intraperitoneal Versus Intravenous Chemotherapy Following Neoadjuvant Chemotherapy and Optimal Debulking Surgery in Epithelial Ovarian Cancer
49. Mental Health Services Use by Melanoma Patients Receiving Adjuvant Interferon: Association of Pre-treatment Mental Health Care with Early Discontinuation
50. The Evidence Driven Dosimetric Constraints From Outcome Analysis of H&N Patients’ Data from NRG Oncology RTOG 0522 Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.